



Washington State Health Care Authority
Prescription Drug Program

P.O. Box 91132 • Seattle, Washington 98111-9232
206-521-2027 • FAX 206-521-2001 • TTY 360-923-2701 • www.rx.wa.gov

CORRECTED NOTICE RE: Atypical Antipsychotic Drug Class

August 18, 2006

Dear Interested Party:

Following recommendations by the Washington State Pharmacy and Therapeutics Committee, the Department of Social and Health Services - Health and Recovery Services Administration (DSHS-HRSA), the Health Care Authority - Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List:

Atypical Antipsychotics

aripiprazole (Abilify ®)
clozapine §
clozapine oral disintegrating (FazaClo ®)
ziprasidone (Geodon ®)
ziprasidone injectable (Geodon ® vial) *
risperidone (Risperdal ®)

risperidone (Risperdal ® Consta ®) *
risperidone oral disintegrating (Risperdal-M ®)
quetiapine (Seroquel ®)
olanzapine (Zyprexa ®)
olanzapine oral disintegrating (Zyprexa ® Zydis ®)
olanzapine injectable (Zyprexa ® vial) *

* New patients requiring injectable administration forms may be subjected to expedited review by HRSA. Injectable administration forms are a non-covered benefit for L&I in an outpatient setting (WAC 296-20-03014(1)).

§ Generic products only.

Each agency will use the common PDL according to its benefit structure.

All agencies will implement the Atypical Antipsychotics class on October 1, 2006.

If you have other questions or comments regarding this announcement, please contact Erika Clayton at (360) 923-2736 or by email at pdp@hca.wa.gov.

Sincerely,

Duane Thurman
Director, Prescription Drug Program